DocPlanner acquires Jameda to enter in Germany’s online healthcare space

POLAND – Polish healthcare platform and world’s largest online healthcare marketplace DocPlanner, has bought its German counterpart, Jameda in a big move that catapults it into Europe’s largest healthtech market. DoPlanner will invest significant capital and global expertise in Jameda as part of the acquisition, with a focus on rapidly growing the company’s sales, customer care, and marketing teams. The purchase price was not disclosed, but DocPlanner will add more than 200 new team members to Jameda as part of the agreement, investing more than a quarter billion euros (US$280.54)…

Read More

Sterling Pharma Solutions ramps up manufacturing capacity with £10m investment

UNITED KINGDOM – Sterling Pharma Solutions, a contract development and manufacturing firm, has announced a £10 million (US$13.5 million) multi-year investment strategy for its Dudley, UK, facility. This latest investment, which is part of Sterling’s multi-year investment strategy at its Dudley site, will include the construction and commissioning of new process development laboratories, as well as the installation of additional commercial-scale manufacturing equipment to meet growing demand for small-molecule API manufacturing. The project, which is expected to be completed in mid-2022, includes the installation of a 4.5 cubic metre hydrogenator…

Read More

Boehringer Ingelheim’s Jardiance scores marketing nod in India for additional indication

INDIA – Indian drug regulator, the Drugs Controller General of India (DCGI) has given Boehringer Ingelheim permission to market Jardiance (empagliflozin) in India for an additional indication to reduce heart failure in adults. The approval is based on the additional data indicating that the drug significantly lowers the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and a low ejection fraction. Heart failure is a common and serious complication of a heart attack that occurs when the heart is unable to pump enough blood…

Read More

Zydus Cadila gets USFDA approval to market generic cancer drug in US

USA – Zydus Cadila, a pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration to market Decitabine injection, which is used to treat certain types of cancer, in the United States. According to Zydus Cadila, the company has received final approval from the US Food and Drug Administration (USFDA) for Decitabine for Injection in the strength of 50 mg/vial single-dose vial. Zydus Pharmaceuticals USA Inc, a subsidiary of the company, has been granted competitive generic therapy (CGT) designation for the product, making it…

Read More

Zambia receives massive donations of Covid-19 facemasks from Germany

ZAMBIA – Over the past months, the Ministry of Health of the Federal Republic of Germany has made in-kind donations of surgical and medical masks to the World Health Organization (WHO) and more than 120 million face masks have been distributed to 100 countries all over the world. As part of this donation, the WHO country office in Zambia received 924,000 surgical and medical face masks for its work in Zambia to support the Ministry of Health’s response to the COVID-19 pandemic. The kind support from the Government of Germany…

Read More

WHO: Coronavirus cases declining in all continents except Europe

SWITZERLAND -The World Health Organization has reported that COVID-19 deaths increased by 10% in Europe in the previous week, making it the only region in the world where both coronavirus cases and fatalities are steadily increasing. It was the sixth week in a row that infections and deaths increased across the continent. In its weekly report on the pandemic, the United Nations Health Organization said that there were about 3.1 million new cases worldwide, a 1% increase from the previous week. Nearly two-thirds of coronavirus infections — 1.9 million —…

Read More

BioMed X Institute, Merck successfully complete fourth project in oncology

GERMANY – BioMed X, a German independent research institute has announced the successful completion of the DNA Damage in Cancer (DDC) research project in collaboration with Merck. Merck has extended the collaboration for a new oncology research project as a result of the project’s successful completion. The extension emphasizes the two partners’ strong relationship and reflects BioMed X’s expertise in biomedical innovation. Merck KGaA, Darmstadt, Germany, sponsored the DDC project, which began in 2016. Team DDC, led by Dr. Balca Mardin, used cancer genomics, genetic screening approaches, and in vitro…

Read More

Thermo Fisher Scientific introduces new Mass Spec and Chromatography technologies

USA – Thermo Fisher Scientific has introduced new mass spectrometry (MS) instruments, workflows, and software, which it displayed at the 69th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in Philadelphia, Pennsylvania. Thermo Scientific’s Orbitrap Exploris MX mass detector enables biopharmaceutical laboratories to use the multi-attribute method (MAM) and perform intact analysis of monoclonal antibodies, as well as oligonucleotide mass determination and peptide mapping. The new system streamlines the transition of biotherapeutics from development to manufacturing and allows quality control (QC) customers to use…

Read More

Rentschler Biopharma, XL-Protein tie up deal to manufacture therapeutic DNase I

GERMANY – Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and XL-protein, a privately held biopharmaceutical company in Germany, have formed a partnership to develop a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I). The new innovation utilized Rentschler Biopharma’s expertise in bioprocess development expertise and XL- protein proprietary’s PASylation technology to develop a modified DNase I with significantly increased activity and extended pharmacokinetic profile. Thilo Grob, vice president Process Science at Rentschler Biopharma SE, commenting on this development said: “This highly successful collaboration was…

Read More

Hyloris announces approval of novel drug for post-operation pain management

BELGIUM – Hyloris Pharmaceuticals SA, a specialty biopharmaceutical company dedicated to addressing unmet medical needs by reinventing existing medications, has announced the expansion of the European footprint of Maxigesic IV to treat post-operative pain in the UK. Hyloris Pharmaceuticals has a diverse pipeline of 13 reformulated and repurposed value-added medicines that have the potential to outperform existing medications. In addition, the company is developing and registering three high barrier generic products. Two products are currently in the early stages of commercialization with partners: Sotalol IV for atrial fibrillation treatment and…

Read More